{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:32:32Z","timestamp":1771540352948,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ophtha.2016.06.043","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T14:10:39Z","timestamp":1470406239000},"page":"2232-2247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial"],"prefix":"10.1016","volume":"123","clinical-trial-number":[{"clinical-trial-number":"nct00781859","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00798317","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01429441","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pravin U.","family":"Dugel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Tolentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Feiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8678-1693","authenticated-orcid":false,"given":"Petra","family":"Kozma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.06.043_bib1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/IAE.0000000000000519","article-title":"Safety profile of ocriplasmin for symptomatic vitreomacular adhesion: a comprehensive analysis of premarketing and postmarketing experiences","volume":"35","author":"Hahn","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.06.043_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMoa1110823","article-title":"Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes","volume":"367","author":"Stalmans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.06.043_bib3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaophthalmol.2013.8142","article-title":"Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection","volume":"132","author":"Fahim","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib4","first-page":"1","article-title":"Persistent retinal changes after intravitreal ocriplasmin","author":"Margo","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.ophtha.2016.06.043_bib5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3928\/23258160-20151008-09","article-title":"Post-market experience with ocriplasmin including chronic electrophysiologic changes","volume":"46","author":"Small","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2016.06.043_bib6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/0974-9233.51982","article-title":"OCT\u2013an insight into retinal disorders","volume":"15","author":"Keshavamurthy","year":"2008","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib8","unstructured":"Schuman JS. Introduction to optical coherence tomography technology: time-domain and spectral-domain including similarities and differences between these technologies. Presented at: FDA AGS Workshop, October 5, 2012, Silver Spring, MD."},{"key":"10.1016\/j.ophtha.2016.06.043_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/910641","article-title":"Optical coherence tomography in the diagnosis and monitoring of retinal diseases","volume":"2013","author":"Talu","year":"2013","journal-title":"ISRN Biomedical Imaging"},{"key":"10.1016\/j.ophtha.2016.06.043_bib10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/eye.2013.94","article-title":"Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin","volume":"27","author":"Freund","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2016.06.043_bib11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/bjophthalmol-2013-304219","article-title":"Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome","volume":"98","author":"Singh","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ophtha.2014.07.045","article-title":"Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials","volume":"122","author":"Haller","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.06.043_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00417-015-3031-1","article-title":"Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study","volume":"254","author":"Chatziralli","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib14","unstructured":"Coskey A, Brown DM, Hooten C, et\u00a0al. Ocriplasmin for vitreomacular adhesion (VMA) in the clinical setting: rates of VMA release, development of macular hole, and visual outcomes. Presented at: The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 4\u20138, 2014, Orlando, FL."},{"key":"10.1016\/j.ophtha.2016.06.043_bib15","unstructured":"Diaz-Rohena R, Flores-Sanchez B. Ocriplasmin in clinical practice. Presented at: Pan-American Society of Retina & Vitreous (SPRV) Congress, June 11\u201314, 2014, San Juan, Puerto Rico."},{"key":"10.1016\/j.ophtha.2016.06.043_bib16","series-title":"For suitable sVMA patients, ocriplasmin has \u2018no down side\u2019. Ocular Surgery News, Improving Patient Outcomes in Symptomatic VMA (Suppl)","first-page":"7","author":"Fineman","year":"2013"},{"key":"10.1016\/j.ophtha.2016.06.043_bib17","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3928\/23258160-20130715-05","article-title":"Initial outcomes following intravitreal ocriplasmin for treatment of symptomatic vitreomacular adhesion","volume":"44","author":"Kim","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2016.06.043_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.sjopt.2014.02.002","article-title":"A\u00a0retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction","volume":"28","author":"Knudsen","year":"2014","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ajo.2015.01.034","article-title":"Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes","volume":"159","author":"Sharma","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2014.09.015","article-title":"Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin","volume":"159","author":"Warrow","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib21","unstructured":"Haines N, Copeland V, Kurup S, et\u00a0al. Outcomes of treatment with intravitreal ocriplasmin for vitreomacular traction syndrome and macular holes at the Wake Forest Eye Center. Presented at: American Society of Retina Specialists (ASRS) Annual Meeting, August 9\u201313, 2014, San Diego, CA."},{"key":"10.1016\/j.ophtha.2016.06.043_bib22","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.ophtha.2014.07.044","article-title":"Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography","volume":"121","author":"Itoh","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.06.043_bib23","first-page":"48","article-title":"Improving success with pharmacologic management of symptomatic VMA","volume":"January\/February","author":"Khanani","year":"2015","journal-title":"Retina Today"},{"key":"10.1016\/j.ophtha.2016.06.043_bib24","series-title":"New injection give the \u2018wait and see\u2019 patient a chance for symptom relief. Ocular Surgery News, Improving Patient Outcomes in Symptomatic VMA (Suppl)","first-page":"4","author":"Lakhanpal","year":"2013"},{"key":"10.1016\/j.ophtha.2016.06.043_bib25","unstructured":"Maier MM, Bonse S, Frank C, et\u00a0al. Jetrea (ocriplasmin) as a treatment option for symptomatic vitreomacular traction with or without macular hole (\u2264400 \u03bcm) \u2013 first clinical experience. Presented at: The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 4\u20138, 2014, Orlando, FL."},{"key":"10.1016\/j.ophtha.2016.06.043_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3928\/23258160-20150213-21","article-title":"Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion","volume":"46","author":"Meyer","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ophtha.2016.06.043_bib27","unstructured":"Nasir M, Pieramici D, Castellarin A. Intravitreal ocriplasmin for vitreomacular adhesion syndrome: initial experience of multi-physician retina practice. Presented at: American Society of Retina Specialists (ASRS) Annual Meeting, August 24\u201328, 2013, Toronto, Canada."},{"key":"10.1016\/j.ophtha.2016.06.043_bib28","unstructured":"Nudleman E, Franklin MS, Ruby AJ, Wolfe JD. Ocriplasmin for vitreomacular adhesion: aftermarket experience and findings. Presented at: American Society of Retina Specialists (ASRS) Annual Meeting, August 9\u201313, 2014, San Diego, CA."},{"key":"10.1016\/j.ophtha.2016.06.043_bib29","unstructured":"O'Neill BP, Shah AP, Coney JM. Resolution of vitreomacular traction using ocriplasmin (JETREA) and its potential role in diabetic macular edema. Presented at: The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 4\u20138, 2014, Orlando, FL."},{"key":"10.1016\/j.ophtha.2016.06.043_bib30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/IAE.0000000000000544","article-title":"Outer retina reflectivity changes on SD OCT after intravitreal ocriplasmin for vitreomacular traction and macular hole","volume":"35","author":"Quezada-Ruiz","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.06.043_bib31","unstructured":"Roth D, Feng HL, Modi KK, et\u00a0al. Predictors of success with intravitreal ocriplasmin in the treatment of symptomatic vitreomacular adhesion. Presented at: The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 4\u20138, 2014, Orlando, FL."},{"key":"10.1016\/j.ophtha.2016.06.043_bib32","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1167\/iovs.15-16409","article-title":"The plane of vitreoretinal separation and results of vitrectomy surgery in patients given ocriplasmin for idiopathic macular hole","volume":"56","author":"Steel","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.06.043_bib33","unstructured":"Torres W. Initial outcomes of intravitreal ocriplasmin (Jetrea) at Sarasota Retina Institute. Presented at: 28th Annual Sarasota Vitreo-Retinal Update Course, February 13\u201315, 2014, Sarasota, FL."},{"key":"10.1016\/j.ophtha.2016.06.043_bib34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/IAE.0000000000000507","article-title":"Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology","volume":"35","author":"Willekens","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.06.043_bib35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000370024","article-title":"Incomplete vitreomacular traction release using intravitreal ocriplasmin","volume":"5","author":"Chin","year":"2014","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/bjophthalmol-2014-305620","article-title":"Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?","volume":"99","author":"Hager","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.06.043_bib37","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/IAE.0000000000000542","article-title":"Transient vision loss after ocriplasmin injection","volume":"35","author":"Reiss","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.06.043_bib38","doi-asserted-by":"crossref","DOI":"10.17925\/EOR.2015.09.02.141","article-title":"Ocriplasmin efficacy: an analysis of real-world results from 2013 to 2015","author":"Kuppermann","year":"2015","journal-title":"Eur Ophthal Rev"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016305115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016305115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T07:54:41Z","timestamp":1536479681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016305115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0161642016305115"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.06.043","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}